German Cannabis Legalization Rollback: June 30, 2026 Update
German state interior ministers are moving to roll back federal cannabis legalization despite supporting evidence, potentially disrupting implementation and patient access. This policy shift reflects broader tensions between regulatory frameworks and…
Policy Watch: 20 Regulatory Updates — June 22, 2026
This update covers DEA synthetic opioids schedule I placement actions affecting clinical and regulatory landscapes in 2026. These changes influence substance classification and patient care considerations. Stay informed on the latest controlled…
Schedules of Controlled Substances: Rescheduling FDA-Approved Marijuana Products
The DEA rescheduling Schedule III cannabis marks a pivotal regulatory change for FDA approved cannabis products. This shift facilitates improved medical cannabis access under federal law. Clinicians and patients should understand the implications of this…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA has issued the cumyl-pegaclone schedule i designation, reflecting its high abuse potential and lack of accepted medical use. This designation highlights regulatory efforts to control synthetic cannabinoids. Clinicians should be aware of the risks…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA has issued temporary scheduling orders placing 2-fluorodeschloroketamine into Schedule I. These orders address emerging synthetic drugs and their regulatory challenges. Temporary scheduling orders are critical for managing novel substances with…
Policy Watch: 20 Regulatory Updates — June 21, 2026
This Policy Watch covers schedules of controlled substances placement June 2026 updates with 20 key regulatory items. The DEA's recent actions focus on synthetic cannabinoids and other substances. These changes affect clinical relevance and regulatory…
International Cannabis Policies and Their Association with Cannabis Use, Cannabis Use Disorder, and Other Psychiatric Disorders
International cannabis policies shape cannabis use and cannabis use disorder prevalence worldwide. Commercialized legalization is linked to increased cannabis use disorder rates. However, associations with broader psychiatric disorders remain…
Policy Watch: 20 Regulatory Updates — June 19, 2026
This update covers the DEA Schedule I synthetic cannabinoids control update as of June 19, 2026. It details regulatory actions impacting synthetic cannabinoids and related substances. The report informs clinical practice and legal considerations.
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA synthetic cannabinoids Schedule I placement 2026 update includes cumyl-pegaclone, a synthetic cannabinoid now classified under Schedule I. This reflects regulatory efforts to control emerging psychoactive substances with high abuse potential.…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA has enacted synthetic ketamine analog regulation by temporarily placing 2-fluorodeschloroketamine in Schedule I. This action highlights the challenges of controlling emerging designer drugs. Clinicians should monitor these regulatory changes…